Triple Negative Breast Cancer Clinical Trials
Triple Negative Breast Cancer clinical trials evaluate new drugs, immunotherapies, radiation approaches, and combination treatments for triple Negative Breast Cancer. Corterve aggregates actively recruiting Triple Negative Breast Cancer studies from the public ClinicalTrials.gov registry so you can browse them by location and eligibility. Many oncology trials enroll patients at different stages of disease, including newly diagnosed and previously treated. This is general information, not medical advice — review any study with your oncology care team before enrolling.
Recruiting Triple Negative Breast Cancer studies
- Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast CancerNCT07652242PHASE1Immunomic Therapeutics, Inc.Grand Rapids, Michigan
- Evolutionary Clinical Trial for Novel Biomarker-Driven TherapiesNCT07340541PHASE2UNC Lineberger Comprehensive Cancer CenterNew Haven, Connecticut
- Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T CellsNCT06347068PHASE1UNC Lineberger Comprehensive Cancer CenterChapel Hill, North Carolina
- Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal CancersNCT06562192PHASE1Novartis PharmaceuticalsBirmingham, Alabama
- A Phase 1 of CTX-8371 in Patients With Advanced MalignanciesNCT06150664PHASE1Compass TherapeuticsMargate, Florida
- A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid TumorsNCT06465069PHASE1Eli Lilly and CompanyDuarte, California
- A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid TumorsNCT07318805PHASE1PfizerDuarte, California
- A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid TumorsNCT05377996PHASE1, PHASE2Day One Biopharmaceuticals, Inc.Phoenix, Arizona
- Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast CancerNCT06637306EARLY_PHASE1Rima PatelNew York, New York
- A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory CarcinomasNCT06999187PHASE1Dren BioDenver, Colorado
- Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab AdizutecanNCT05005403PHASE1AbbVieDuarte, California
- Cardiac Outcomes With Near-Complete Estrogen DeprivationNCT05309655NADuke UniversityDurham, North Carolina
See all 89 recruiting Triple Negative Breast Cancer trials →
Triple Negative Breast Cancer trials by state
Triple Negative Breast Cancer trials by metro
Frequently asked questions
- How do I find recruiting Triple Negative Breast Cancer clinical trials?
- Corterve aggregates actively recruiting Triple Negative Breast Cancer studies from the public ClinicalTrials.gov registry. Browse the studies listed on this page or take a free health assessment to see trials you may qualify for based on your profile.
- Are Triple Negative Breast Cancer clinical trials free to join?
- Study participation is typically free — research sponsors cover the cost of the investigational treatment and study-related visits. Many trials also compensate participants for time and travel. Details vary by study.
- Who can take part in a Triple Negative Breast Cancer clinical trial?
- Each study has its own eligibility criteria (for example age, disease stage, and prior treatments). This page is general information and not medical advice; discuss any specific trial with your healthcare provider to confirm whether it is appropriate for you.